{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:52Z","timestamp":1786735852645,"version":"build-2736575974"},"reference-count":102,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Ophthalmol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijo.ijo_975_18","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T05:29:55Z","timestamp":1542778195000},"page":"1727","source":"Crossref","is-referenced-by-count":25,"title":["Current management strategy of polypoidal choroidal vasculopathy"],"prefix":"10.4103","volume":"66","author":[{"given":"TimothyY Y","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChristineP S","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0301-4738.245646-1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","author":"Ciardella","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-2","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","article-title":"Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics","author":"Sho","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"key-10.4103\/0301-4738.245646-4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","article-title":"Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease?","author":"Laude","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"key-10.4103\/0301-4738.245646-5","doi-asserted-by":"crossref","first-page":"41386","DOI":"10.1038\/srep41386","article-title":"Systemic, ocular and genetic risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Singaporeans","author":"Cheung","year":"2017","journal-title":"Sci Rep"},{"key":"key-10.4103\/0301-4738.245646-6","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00417-018-4020-y","article-title":"A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients","author":"Chen","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-7","first-page":"1","article-title":"Prevalence and risk factors for polypoidal choroidal vasculopathy in a general Japanese population: The Hisayama study","author":"Fujiwara","year":"2018","journal-title":"Semin Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/eye.2014.226","article-title":"FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy","author":"Liang","year":"2014","journal-title":"Eye (Lond)"},{"key":"key-10.4103\/0301-4738.245646-9","doi-asserted-by":"crossref","first-page":"28639","DOI":"10.1038\/srep28639","article-title":"HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy from exudative age-related macular degeneration","author":"Ng","year":"2016","journal-title":"Sci Rep"},{"key":"key-10.4103\/0301-4738.245646-10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/jhg.2017.83","article-title":"Shared genetic variants for polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration in East Asians","author":"Fan","year":"2017","journal-title":"J Hum Genet"},{"key":"key-10.4103\/0301-4738.245646-11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/IAE.0b013e31823beb14","article-title":"Polypoidal choroidal vasculopathy: Simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings","author":"Khan","year":"2012","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-13","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1097\/IAE.0000000000001346","article-title":"Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness","author":"Lee","year":"2016","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-14","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00417-015-2933-2","article-title":"The natural history of polypoidal choroidal vasculopathy: A multi-center series of untreated Asian patients","author":"Cheung","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","article-title":"Polypoidal choroidal vasculopathy: Natural history","author":"Uyama","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-16","first-page":"417","article-title":"[Criteria for diagnosis of polypoidal choroidal vasculopathy] [Article in Japanese]","author":"Japanese","year":"2005","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"key-10.4103\/0301-4738.245646-17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","article-title":"EVEREST study report 2: Imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy","author":"Tan","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-19","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/IAE.0000000000000482","article-title":"Improved specificity of polypoidal choroidal vasculopathy diagnosis using a modified EVEREST criteria","author":"Cheung","year":"2015","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: Evidence-based guidelines for clinical diagnosis and treatment","author":"Koh","year":"2013","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","article-title":"Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy","author":"Spaide","year":"1995","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-22","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/IAE.0000000000000255","article-title":"Understanding indocyanine green angiography in polypoidal choroidal vasculopathy: The group experience with digital fundus photography and confocal scanning laser ophthalmoscopy","author":"Cheung","year":"2014","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/eye.2016.71","article-title":"The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting","author":"Ozkaya","year":"2016","journal-title":"Eye"},{"key":"key-10.4103\/0301-4738.245646-24","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1111\/aos.12110","article-title":"Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types","author":"Kawamura","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1136\/bjophthalmol-2016-309144","article-title":"Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy","author":"Jeong","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000360308","article-title":"Comparison of the outcomes of photodynamic therapy between two angiographic subtypes of polypoidal choroidal vasculopathy","author":"Honda","year":"2014","journal-title":"Ophthalmologica"},{"key":"key-10.4103\/0301-4738.245646-27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0161-6420(94)31303-0","article-title":"Adverse reactions due to indocyanine green","author":"Hope-Ross","year":"1994","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.245646-28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/IAE.0b013e318156db60","article-title":"Cross-sectional and en face optical coherence tomographic features of polypoidal choroidal vasculopathy","author":"Saito","year":"2008","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1097\/IAE.0b013e318285cbb3","article-title":"Optical coherence tomographic enhanced depth imaging of polypoidal choroidal vasculopathy","author":"Yang","year":"2013","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-30","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IAE.0000000000000794","article-title":"Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography","author":"Liu","year":"2016","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-31","first-page":"1028","article-title":"En face enhanced depth imaging optical coherence tomography of polypoidal choroidal vasculopathy","author":"Semoun","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IAE.0000000000000794","article-title":"Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography","author":"Liu","year":"2016","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/eye.2013.106","article-title":"Ocular perfusion pressure and choroidal thickness in eyes with polypoidal choroidal vasculopathy, wet-age-related macular degeneration, and normals","author":"Rishi","year":"2013","journal-title":"Eye (Lond)"},{"key":"key-10.4103\/0301-4738.245646-34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1167\/iovs.16-20519","article-title":"Classification of exudative age-related macular degeneration with pachyvessels on en face swept-source optical coherence tomography","author":"Ng","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.245646-35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/IAE.0000000000000645","article-title":"Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after anti-VEGF treatment in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","author":"Lee","year":"2016","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-36","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1097\/IAE.0000000000001070","article-title":"Hyperreflectie foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab","author":"Chatziralli","year":"2016","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamaophthalmol.2014.3616","article-title":"Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography","author":"Spaide","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1167\/iovs.15-18898","article-title":"Characteristics of polypoidal choroidal vasculopathy evaluated by optical coherence tomography angiography","author":"Tomiyasu","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.245646-39","first-page":"45","article-title":"Comparison of indocyanine green angiography and optical coherence tomographic angiography in polypoidal choroidal vasculopathy","author":"Takayama","year":"2016","journal-title":"Eye"},{"key":"key-10.4103\/0301-4738.245646-40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0000000000001702","article-title":"Polypoidal choroidal vasculopathy upon optical coherence tomographic angiography","author":"Chan","year":"2018","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-41","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1097\/IAE.0000000000000777","article-title":"Optical coherence tomography angiography of polypoidal choroidal vasculopathy and polypoidal choroidal neovascularization","author":"Inoue","year":"2015","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-42","first-page":"3479695","article-title":"Sensitivity, specificity, and limitations of optical coherence tomography angiography in diagnosis of polypoidal choroidal vasculopathy","author":"Huang","year":"2017","journal-title":"J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-43","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00417-007-0564-y","article-title":"Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography","author":"Gomi","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-44","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/IAE.0000000000001034","article-title":"Patterns of fundus autofluorescence defects in neovascular related macular degeneration subtypes","author":"Ozkok","year":"2016","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-45","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.ophtha.2012.02.016","article-title":"Fundus autofluorescence in polypoidal choroidal vasculopathy","author":"Yamagishi","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.245646-46","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00417-018-3980-2","article-title":"Characteristic appearances of fundus autofluorescence in treatment-naive and active polypoidal choroidal vasculopathy: A retrospective study of 170 patients","author":"Zhao","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-47","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s004170000180","article-title":"Polypoidal choroidal vasculopathy in Caucasians","author":"Lafaut","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/bjo.86.8.892","article-title":"Polypoidal choroidal vasculopathy in Chinese patients","author":"Kwok","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0021-5155(03)00042-X","article-title":"A study of laser photocoagulation for polypoidal choroidal vasculopathy","author":"Yuzawa","year":"2003","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-50","first-page":"145","article-title":"Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy.Eye (Lond)","author":"Lee","year":"2009","journal-title":""},{"key":"key-10.4103\/0301-4738.245646-51","doi-asserted-by":"crossref","unstructured":"Cheung CM, Yeo I, Li X, Mathur R, Lee SY, Chan CM, et al. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. Am J Ophthalmol 2013;155:295-304.e1.","DOI":"10.1016\/j.ajo.2012.08.002"},{"key":"key-10.4103\/0301-4738.245646-52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00417-010-1307-z","article-title":"Verteporfin PDT for non-standard indications--a review of current literature","author":"Chan","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00006982-200210000-00001","article-title":"Treatment of polypoidal choroidal vasculopathy with photodynamic therapy","author":"Spaide","year":"2002","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-54","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","article-title":"Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series","author":"Chan","year":"2004","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.245646-55","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000076844","article-title":"Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula","author":"Lee","year":"2004","journal-title":"Ophthalmologica"},{"key":"key-10.4103\/0301-4738.245646-56","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00417-005-1139-4","article-title":"Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin","author":"Silva","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10384-007-0452-3","article-title":"Role of photodynamic therapy in polypoidal choroidal vasculopathy","author":"Akaza","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-58","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/IAE.0000000000000499","article-title":"Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: Retrospective Study and Systematic Review","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.iae.0000233647.78726.46","article-title":"Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy","author":"Hirami","year":"2007","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-60","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4103\/ijo.IJO_174_17","article-title":"Incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy following photodynamic therapy in Indian subjects","author":"Rishi","year":"2017","journal-title":"Indian J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0301-4738","issn-type":"print"},{"key":"key-10.4103\/0301-4738.245646-61","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bjophthalmol-2017-310448","article-title":"Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy","author":"Hikichi","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-63","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-64","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/IAE.0b013e31820d3f3f","article-title":"Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy","author":"Lai","year":"2011","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-65","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/eye.2013.179","article-title":"Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy","author":"Inoue","year":"2013","journal-title":"Eye (Lond)"},{"key":"key-10.4103\/0301-4738.245646-66","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","article-title":"LAPTOP Study: A 24-Month Trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy","author":"Oishi","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.245646-67","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-68","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/IAE.0000000000001195","article-title":"Treat-and-extend regimen using ranibizumab for polypoidal choroidal vasculopathy.One-Year Results","author":"Pak","year":"2017","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-69","first-page":"74","article-title":"Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis)","author":"Kokame","year":"2014","journal-title":"Trans Am Ophthalmol Soc"},{"key":"key-10.4103\/0301-4738.245646-70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjo.2008.150029","article-title":"Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results","author":"Kokame","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-71","doi-asserted-by":"crossref","unstructured":"Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-Month LAPTOP study results. Am J Ophthalmol 2013;156:644-51.e1.","DOI":"10.1016\/j.ajo.2013.05.024"},{"key":"key-10.4103\/0301-4738.245646-72","doi-asserted-by":"crossref","unstructured":"Miyamoto N, Mandai M, Oishi A, Nakai S, Honda S, Hirashima T, et al. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br J Ophthalmol 2018.doi: 10.1136\/bjophthalmol-2018-312419.","DOI":"10.1136\/bjophthalmol-2018-312419"},{"key":"key-10.4103\/0301-4738.245646-73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","article-title":"Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy","author":"Cho","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-74","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/IAE.0000000000001047","article-title":"Angiographic findings of ranibizumab-resistant polypoidal choroidal vasculopathy after switching to a treat-and-extend regimen with intravitreal aflibercept","author":"Azuma","year":"2016","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-75","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00417-014-2838-5","article-title":"Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","author":"Kawashima","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-76","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00417-016-3489-5","article-title":"Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study","author":"Lee","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-77","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/OPTH.S129164","article-title":"Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy","author":"Arakawa","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-78","doi-asserted-by":"crossref","unstructured":"Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, et al. One-Year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol 2015;159:853-60.e1.","DOI":"10.1016\/j.ajo.2015.01.018"},{"key":"key-10.4103\/0301-4738.245646-79","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","article-title":"One-Year results of intravitreal aflibercept for polypoidal choroidal vasculopathy","author":"Yamamoto","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.245646-80","doi-asserted-by":"crossref","unstructured":"Maruyama-Inoue M, Sato S, Yamane S, Kadonosono K. Intravitreal injection of aflibercept in patients with polypoidal choroidal vasculopathy: A 3-year follow up. Retina 2017. doi: 10.1097\/IAE.0000000000001818.","DOI":"10.1097\/IAE.0000000000001818"},{"key":"key-10.4103\/0301-4738.245646-81","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10384-016-0492-7","article-title":"One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy","author":"Hosokawa","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-82","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","article-title":"Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy","author":"Morimoto","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-83","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2147\/DDDT.S67536","article-title":"Profile of conbercept in the treatment of neovascular age-related macular degeneration","author":"Sun","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"key-10.4103\/0301-4738.245646-84","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/IAE.0000000000000875","article-title":"Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: Subgroup analysis of the Aurora study","author":"Qu","year":"2016","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-85","doi-asserted-by":"crossref","unstructured":"Huang Z, Ding Q, Yan M, Lian H, Chen Z, Chen X, et al. Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy. Retina 2018.doi: 10.1097\/IAE.0000000000002035.","DOI":"10.1097\/IAE.0000000000002035"},{"key":"key-10.4103\/0301-4738.245646-86","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.2007.135103","article-title":"Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy","author":"Lai","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-87","doi-asserted-by":"crossref","unstructured":"Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina 2011;846-56.","DOI":"10.1097\/IAE.0b013e3181f84fdf"},{"key":"key-10.4103\/0301-4738.245646-88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy","author":"Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-89","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000175312","article-title":"Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy","author":"Song","year":"2009","journal-title":"Ophthalmologica"},{"key":"key-10.4103\/0301-4738.245646-90","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10384-010-0813-1","article-title":"Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab","author":"Tsujikawa","year":"2010","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-91","first-page":"561","article-title":"Intravitreal ziv-aflibercept: Clinical Effects and Econmic Impact","author":"Singh","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"key-10.4103\/0301-4738.245646-92","doi-asserted-by":"crossref","unstructured":"Videkar C, Kapoor A, Chhablani J, Narayanan R. Ziv-aflibercept: A novel option for the treatment of polypoidal choroidal vasculopathy. BMJ Case Rep 2015;2015.doi: 10.1136\/bcr-2015-212988.","DOI":"10.1136\/bcr-2015-212988"},{"key":"key-10.4103\/0301-4738.245646-93","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1111\/aos.13533","article-title":"Treatment outcomes of ziv-aflibercept for treatment-na\u00efve polypoidal choroidal vasculopathy","author":"Chan","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-94","doi-asserted-by":"crossref","unstructured":"Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010;149:947-54.e1.","DOI":"10.1016\/j.ajo.2009.12.038"},{"key":"key-10.4103\/0301-4738.245646-95","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000330793","article-title":"Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy","author":"Kim","year":"2011","journal-title":"Ophthalmologica"},{"key":"key-10.4103\/0301-4738.245646-96","doi-asserted-by":"crossref","unstructured":"Kang HM, Koh HJ, Lee CS, Lee SC. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: Long-term visual outcome. Am J Ophthalmol 2014;157:598-606.e1.","DOI":"10.1016\/j.ajo.2013.11.015"},{"key":"key-10.4103\/0301-4738.245646-97","first-page":"1119","article-title":"Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy","author":"Jain","year":"2018","journal-title":"Indian J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0301-4738","issn-type":"print"},{"key":"key-10.4103\/0301-4738.245646-98","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.exer.2007.05.008","article-title":"Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo","author":"Lowe","year":"2007","journal-title":"Exp Eye Res"},{"key":"key-10.4103\/0301-4738.245646-99","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","article-title":"Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan Study","author":"Gomi","year":"2015","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-100","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET Study: A randomized clinical trial","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"key-10.4103\/0301-4738.245646-101","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/IAE.0000000000001614","article-title":"One-year results of half- versus standard-dose photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy","author":"Wong","year":"2018","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.245646-102","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1097\/IAE.0000000000000498","article-title":"Half-dose photodynamic therapy combined with bevacizumab for polypoidal choroidal vasculopathy","author":"Lee","year":"2015","journal-title":"Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:34:21Z","timestamp":1786732461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_975_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":102,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"alternative-id":["245646"],"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_975_18","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}